Benzinga | Mar 15, 2021 08:06AM EDT

Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference

Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021.



Cue Biopharma will provide a corporate update highlighting clinical progress with CUE-101, the lead Immuno-STAT(tm) (Selective Targeting and Alteration of T cells) platform-based therapeutic, in clinical trials for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The presentation will also focus on the Company's platform developments and pipeline progress including the CUE-400 series, a novel class of therapeutic molecules for broad applications in multiple autoimmune diseases.